Analytical Data
-
Gene name
UCMA
- Application
-
Alternative Names
C10orf49; GRP; Ucma-C; Gla-rich protein
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
B9TQX4
-
Expression Region
Ser28~Ile138
-
Molecular Weight
17/20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UCMA (Uromodulin Cystatin-like Multimeric Alpha) is a novel multifunctional protein that has garnered significant attention in recent years due to its potential role in various biological processes, particularly in immune regulation and cell signaling. Initially discovered in the context of kidney function, UCMA is believed to be involved in modulating the immune response and maintaining tissue homeostasis. Research highlights its unique structure, which allows it to form multimeric complexes, enhancing its biological activities. Studies have shown that UCMA may play a protective role in inflammatory diseases and could be crucial in renal pathologies. Furthermore, its implications in the tumor microenvironment suggest that UCMA might influence cancer progression and metastasis, making it a potential target for therapeutic interventions. The exploration of UCMA as a recombinant protein for research purposes has opened new avenues for understanding its mechanisms of action and therapeutic applications, signaling a shift towards more targeted and effective treatment strategies in immunology and oncology. The ongoing investigation into UCMA's structure-function relationship and its interactions with other proteins continues to uncover its significance in health and disease, positioning UCMA as a promising candidate for future biotherapeutics and diagnostic tools.
